Vanguard Health Care ISHARES: How They Stack Up for Modern Portfolios
A clear look at how Vanguard Health Care and iShares Biotechnology compete for space in a diversified portfolio. Lear...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
118 articles
FHLC BBH: Which Healthcare ETF Is Best for Your Portfolio?
Healthcare investing offers breadth and specialty. This guide explains FHLC and BBH, how they differ, and how to deci...
Biogen Paying Billion Company Signals BIIB Turnaround
Biogen’s $1 billion move on a mystery company has investors buzzing. This article breaks down why the deal could be a...
Pfizer's Says Company "Very" Big Balance Sheet for Deals
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
Three Factors That Have Brought Small-Cap Trade to Life
A revival in small-cap stocks is taking shape as three key forces converge. AI-driven demand, a steadier macro backdr...
Wall Street Thinks This Biotech Stock Could Soar 57%
Biotech investing often rides on data, not on dreams. This educational piece uses a fictional company to show how wal...
Lilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
AI Transforming Drug Discovery: Next Biotech Boom Ahead
Artificial intelligence is turbocharging drug discovery, cutting years from development timelines and sparking a surg...
Wall Street Expects This Growth Stock to Double Soon
A biotech growth stock has surged 70% this year as it heads into pivotal phase 3 data and regulatory steps. Here’s wh...
Should Moderna Before Aug.: A Clear Investor Guide for 2026
As Aug. 5 looms, investors debate whether Moderna belongs in a refreshed portfolio. This guide breaks down the cataly...
Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...